Richard Branson takes 23andMe public with his SPAC, as the GlaxoSmithKline partner aims to beef up drug R&D

Max Gelman

Senior Editor

One of the buzziest names in healthcare and delivering personalized medicine directly based on a customer’s genetics went public Thursday, and used a high-profile billionaire� …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Richard Branson takes 23andMe public with his SPAC, as the GlaxoSmithKline partner aims to beef up drug R&D

Max Gelman

Senior Editor

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

New fund will pressure flailing biotechs, as investor frustration boils over

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Richard Bran­son takes 23andMe pub­lic with his SPAC, as the Glax­o­SmithK­line part­ner aims to beef up drug R&D

Senior Editor

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

Richard Branson takes 23andMe public with his SPAC, as the GlaxoSmithKline partner aims to beef up drug R&D